跳至主要内容
临床试验/NCT05201846
NCT05201846Unknown不适用

Effect of Continuous Subcutaneous Insulin Injection in Pediatric Patients With Type 1 Diabetes Using Multiple Daily Insulin Injections

Seoul National University Hospital2 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2022年1月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
66
试验地点
2
主要终点
Time in range

研究概览

简要总结

Prospective, randomized, open-label, two-sequence crossover study to investigate the effects of continuous subcutaneous insulin injection (CSII, using DIA:CONN G8 insulin pump) in pediatric patients with type 1 diabetes using multiple daily insulin (MDI) injection

详细描述

This trial consists of two crossover periods of 5 weeks each (MDI to CSII or CSII to MDI), followed by an extended period of 12 weeks (MDI or CSII). Each intervention period has wash-out period (5 days) excluded from the outcome measurements.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
2 Years 至 17 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •The subject is aged 2-17
  • •The subject with one or more of the below at diagnosis
  • •serum c-peptide < 0.6 ng/mL
  • •positive glutamic acid decarboxylase (GAD) antibody
  • •positive Islet cell antibody
  • •positive anti-Insulin antibody
  • •positive anti-Islet Antigen-2 (IA-2) antibody
  • •The subject was diagnosed with type 1 diabetes ≥ 1 year
  • •The subject is treated with multiple daily insulin injection
  • •The subject must have available continuous glucose monitoring (CGM) data with a percentage of active CGM time ≥ 70% in the past 4 weeks.

排除标准

  • •Subjects who were treated with insulin pump therapy within 12 weeks prior to trial
  • •Any systemic treatment with drugs known to interfere with glucose metabolism within 12 weeks prior to trial
  • •Subjects with underlying hematologic disorders that can affect the HbA1c levels
  • •Subjects with underlying medical disorders that can affect glucose metabolism
  • •Subjects with a neuropsychiatric disorder such as depression or eating disorder
  • •Subjects with underlying thyroid disorders and abnormal thyroid function

研究组 & 干预措施

Continuous subcutaneous insulin infusion

Experimental

Continuous subcutaneous insulin infusion using insulin pump (DIA:CONN G8) with continuous glucose monitoring

干预措施: DIA:CONN G8 insulin pump (Device)

Multiple daily insulin injection

Active Comparator

Multiple daily insulin injection with continuous glucose monitoring

干预措施: Multiple daily insulin injection (Other)

结局指标

主要结局

Time in range

时间窗: 30 days

glucose level between 70-180 mg/dL derived from continuous glucose monitoring

次要结局

  • Coefficient of variation(30 days)
  • Glycated albumin(Changes from baseline to after 30 days of intervention)
  • Children's Depression inventory of patients(At the end of intervention (30 days))
  • Time above range(30 days)
  • Mean sensor glucose(30 days)
  • Quality of life measurements (diabetes-specific) of patients and parents(At the end of intervention (30 days))
  • Perceived stress scale of parents(At the end of intervention (30 days))
  • Quality of life measurements (general) of patients and parents(At the end of intervention (30 days))
  • Time below range(30 days)
  • Glucose management indicator(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Choong Ho Shin

Professor

Seoul National University Hospital

研究点 (2)

Loading locations...

相似试验